HSBC Upgrades Eli Lilly to Hold, Boosts Price Target to $700

HSBC analyst Rajesh Kumar upgraded Eli Lilly to Hold from Sell and lifted the price target to $700 from $675, citing progress on the company's oral weight-loss drug. The trial showed meaningful weight loss in patients with obesity and type 2 diabetes, strengthening Eli Lilly's position in both U.S. and overseas markets. FDA approval is expected in 2026, with projected annual sales of $15.5 billion by 2032.

HSBC analyst Rajesh Kumar has upgraded Eli Lilly (NYSE: LLY) to Hold from Sell, increasing the price target to $700 from $675, following the company's oral weight-loss drug orforglipron's Phase 3 trial results. The trial demonstrated significant weight loss in patients with obesity and type 2 diabetes, strengthening Eli Lilly's position in both U.S. and overseas markets [1].

The latest Phase 3 trial, ATTAIN-2, tested three daily doses of orforglipron in over 1,600 participants across 11 countries. Patients with obesity or overweight and type 2 diabetes lost up to 22.9 pounds (10.5%) at the highest dose over 72 weeks. Participants also saw average reductions in hemoglobin A1C of 1.3% to 1.8%, with 75% of patients at the highest dose reaching diabetes remission thresholds [2].

The trial results highlight orforglipron's potential to offer the convenience of a once-daily pill with a tolerability profile consistent with injectable GLP-1 therapies. Eli Lilly is expected to file for global regulatory approval later this year, with FDA approval anticipated in 2026. The company projects annual sales of $15.5 billion by 2032, driven by the oral weight-loss drug [1].

Eli Lilly's oral GLP-1 drug is positioned to challenge competitors like Novo Nordisk's Wegovy, which is currently the market leader in the weight management market. The company's diversified product portfolio and pipeline, including diabetes and oncology products, further support its growth prospects [1].

Investor sentiment has been volatile, with Eli Lilly's stock price swinging on trial data releases. The latest upgrade by HSBC reflects the analyst's optimism about the company's growth prospects, particularly in the weight management market [1].

References:
[1] https://www.aol.com/prediction-unstoppable-growth-stock-worth-003300575.html
[2] https://www.geneonline.com/eli-lillys-oral-glp-1-weight-loss-pill-clears-third-phase-3-trial-bringing-fda-approval-within-reach/